ProKidney Corp (NASDAQ: PROK) on Friday, plunged -12.36% from the previous trading day, before settling in for the closing price of $5.18. Within the past 52 weeks, PROK’s price has moved between $0.46 and $7.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 21.23%. With a float of $94.29 million, this company’s outstanding shares have now reached $129.54 million.
Let’s determine the extent of company efficiency that accounts for 204 employees. In terms of profitability, gross margin is 100.0%, operating margin of -60453.59%, and the pretax margin is -54267.65%.
ProKidney Corp (PROK) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of ProKidney Corp is 27.29%, while institutional ownership is 41.58%. The most recent insider transaction that took place on Jul 08 ’25, was worth 312,510. In this transaction Chief Regulatory Officer of this company sold 103,480 shares at a rate of $3.02, taking the stock ownership to the 0 shares. Before that another transaction happened on Jul 08 ’25, when Company’s Officer proposed sale 103,480 for $0.61, making the entire transaction worth $62,761.
ProKidney Corp (PROK) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 21.23% per share during the next fiscal year.
ProKidney Corp (NASDAQ: PROK) Trading Performance Indicators
ProKidney Corp (PROK) is currently performing well based on its current performance indicators. A quick ratio of 10.96 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4286.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.60, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of ProKidney Corp (PROK)
Looking closely at ProKidney Corp (NASDAQ: PROK), its last 5-days average volume was 129.19 million, which is a jump from its year-to-date volume of 5.77 million. As of the previous 9 days, the stock’s Stochastic %D was 62.92%.
During the past 100 days, ProKidney Corp’s (PROK) raw stochastic average was set at 61.17%, which indicates a significant increase from 60.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.74 in the past 14 days, which was higher than the 0.20 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.06, while its 200-day Moving Average is $1.40. However, in the short run, ProKidney Corp’s stock first resistance to watch stands at $5.17. Second resistance stands at $5.79. The third major resistance level sits at $6.14. If the price goes on to break the first support level at $4.20, it is likely to go to the next support level at $3.85. Now, if the price goes above the second support level, the third support stands at $3.23.
ProKidney Corp (NASDAQ: PROK) Key Stats
Market capitalization of the company is 1.33 billion based on 292,698K outstanding shares. Right now, sales total 80 K and income totals -61,190 K. The company made 230 K in profit during its latest quarter, and -16,730 K in sales during its previous quarter.
